Countdown toNOPAIN Act:
Days
ASP+6% CMS reimbursement for proven non-opioids used in all outpatient surgical settings is coming January 1, 2025.
Learn more about our therapies by selecting a product below.
ProductsEXPAREL® (bupivacaine liposome injectable suspension) is a local analgesic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain.*
The ioverao system is a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves, interrupting the nerve’s ability to transmit a pain signal.
Proprietary multivesicular liposome (pMVL) technology encapsulates drugs, preserving their molecular structure, and releases them over a desired period of time.
ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) is the first and only approved treatment for osteoarthritis (OA) knee pain utilizing extended-release microsphere technology.
Effective January 1, 2025
NOPAIN ACT
ASP+6% CMS reimbursement for proven non-opioids, like EXPAREL, used in all outpatient surgical settings1-3
ASP, average sales price; CMS, Centers for Medicare and Medicaid Services; NOPAIN, Non-Opioids Prevent Addiction in the Nation.
References: 1. Congress.gov. One hundred seventeenth congress of the United States of America. Accessed June 12, 2024. https://www.congress.gov/117/bills/hr2617/BILLS-117hr2617enr.pdf 2. CMS.gov. Medicare part B drug average sales price. Updated April 2, 2024. Accessed June 13, 2024. https://www.cms.gov/medicare/payment/fee-for-service-providers/part-b-drugs/average-drug-sales-price 3. EXPAREL Prescribing Information. San Diego, CA; Pacira Pharmaceuticals, Inc., November 2023.
